HIGHLIGHTS
- who: Na Zhou from the Sichuan University, China have published the research: Anti-PD-1 antibodies, a novel treatment option for advanced chemoresistant pulmonary lymphoepithelioma carcinoma, in the Journal: (JOURNAL)
- what: The Cox regression analysis was conducted to assess the impact of other clinical factors on PFS and OS. Intriguingly, when the authors focused on the patients of Chinese descent, those with high PD-L1 expression (TPS >30%) tended to have a prolonged infection has been linked to upregulation of PD-L1 expression in malignancies . The authors described 10 previously treated LELC patients receiving PD . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.